Eton Pharmaceuticals (NASDAQ:ETON) Issues Earnings Results

Eton Pharmaceuticals (NASDAQ:ETON) announced its quarterly earnings results on Thursday. The company reported $0.43 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.11 by $0.32, FiscalAI reports. The company had revenue of $37.59 million during the quarter, compared to the consensus estimate of $27.11 million. Eton Pharmaceuticals had a net margin of 12.02% and a return on equity of 47.64%.

Here are the key takeaways from Eton Pharmaceuticals’ conference call:

• Record Q2 performance — Revenue rose 99% year over year to $37.6 million, adjusted EBITDA increased to $16.2 million, and net income reached $11.6 million versus a prior-year loss.
• Eton raised its 2026 outlook, now expecting revenue above $145 million versus prior guidance of more than $120 million, while increasing its adjusted EBITDA margin forecast to above 35% from above 30%.
• HEMANGEOL’s relaunch exceeded expectations, with approximately 95% of patients transitioned to Eton Cares by the end of June; management sees further growth from converting patients using off-label treatments and expects annual patients to exceed 10,000.
• The company added ASN-001, a late-stage topical hemangioma treatment that could address a larger patient population than HEMANGEOL and use the same commercial infrastructure. Eton plans to begin a $4 million bioavailability study shortly, submit an NDA in the second half of 2027, and potentially launch in 2028.
• Eton also advanced KHINDIVI, INCRELEX, Amglidia, DESMODA, Galzin, and ET-700, while adding U.S. rights to IMPAVIDO; however, several opportunities remain dependent on clinical studies, regulatory approvals, or future commercialization efforts.

Eton Pharmaceuticals Stock Up 44.3%

ETON opened at $58.86 on Friday. Eton Pharmaceuticals has a one year low of $14.27 and a one year high of $59.79. The company has a debt-to-equity ratio of 0.62, a quick ratio of 0.88 and a current ratio of 1.21. The stock’s fifty day moving average is $39.06 and its 200-day moving average is $28.59. The company has a market capitalization of $1.61 billion, a PE ratio of 154.89 and a beta of 0.86.

Trending Headlines about Eton Pharmaceuticals

Here are the key news stories impacting Eton Pharmaceuticals this week:

• Positive Sentiment: Quarterly results significantly exceeded expectations: Eton reported adjusted earnings of approximately $0.35–$0.43 per share, compared with consensus estimates ranging from $0.11 to $0.15. Revenue reached $37.59 million, well above the $27.11 million analyst forecast, and the company improved from a loss in the year-ago period. Eton Pharmaceuticals Q2 Earnings and Revenues Beat Estimates
• Positive Sentiment: Strong commercial growth supported the beat: Product sales nearly doubled year over year, increasing 99% in the second quarter. Management raised 2026 revenue guidance to more than $145 million and reiterated a long-term opportunity to generate over $500 million in peak annual sales through organic growth, pipeline products and acquisitions in rare diseases. Eton Pharmaceuticals Reports Second Quarter 2026 Financial Results
• Positive Sentiment: Profitability expectations are improving: Eton expects adjusted EBITDA margins above 35% in 2026, potentially reaching 50% by 2028, while gross margins are projected to expand from roughly 70% to more than 75%. These targets reinforce the market’s view that revenue growth could translate into substantial earnings growth. Eton Pharmaceuticals: No Reason Pharma Can’t Deliver More Great Earnings Like These
• Neutral Sentiment: HC Wainwright maintained a Buy rating and a $65 price target, suggesting continued upside potential, although its estimates imply investors will be focused on whether Eton can sustain the pace of growth.
• Negative Sentiment: HC Wainwright reduced its long-term EPS forecasts for 2027–2030, including lowering its 2030 estimate to $6.53 from $8.65. The revisions create a counterpoint to the upbeat quarterly results and highlight execution and valuation risks after the stock’s rapid advance. HC Wainwright Issues Negative Outlook for ETON Earnings

Insider Transactions at Eton Pharmaceuticals

In other news, insider David Krempa sold 42,797 shares of Eton Pharmaceuticals stock in a transaction that occurred on Friday, May 22nd. The shares were sold at an average price of $33.39, for a total value of $1,428,991.83. Following the transaction, the insider owned 25,249 shares of the company’s stock, valued at $843,064.11. The trade was a 62.89% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this link. Also, Director Jennifer Mckie Adams sold 50,000 shares of the stock in a transaction that occurred on Wednesday, June 17th. The shares were sold at an average price of $32.48, for a total transaction of $1,624,000.00. Following the sale, the director directly owned 50,000 shares of the company’s stock, valued at approximately $1,624,000. This represents a 50.00% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 150,000 shares of company stock worth $4,853,921. 16.49% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Eton Pharmaceuticals

A number of institutional investors and hedge funds have recently modified their holdings of the stock. Quarry LP acquired a new position in shares of Eton Pharmaceuticals in the 3rd quarter worth $37,000. Caitong International Asset Management Co. Ltd purchased a new stake in shares of Eton Pharmaceuticals during the fourth quarter valued at $44,000. Legal & General Group Plc purchased a new stake in shares of Eton Pharmaceuticals during the second quarter valued at $41,000. New York State Common Retirement Fund acquired a new position in shares of Eton Pharmaceuticals in the 2nd quarter valued at $115,000. Finally, State of Wyoming boosted its position in shares of Eton Pharmaceuticals by 50.0% in the 4th quarter. State of Wyoming now owns 8,161 shares of the company’s stock valued at $138,000 after purchasing an additional 2,721 shares during the period. Institutional investors and hedge funds own 27.86% of the company’s stock.

Analyst Upgrades and Downgrades

A number of analysts recently weighed in on the stock. Canaccord Genuity Group increased their price objective on shares of Eton Pharmaceuticals from $60.00 to $68.00 and gave the stock a “buy” rating in a report on Friday. Wall Street Zen raised shares of Eton Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research note on Saturday, June 13th. Weiss Ratings restated a “sell (d-)” rating on shares of Eton Pharmaceuticals in a research report on Friday, July 17th. B. Riley Financial restated a “buy” rating and issued a $70.00 price target (up from $40.00) on shares of Eton Pharmaceuticals in a research note on Friday. Finally, HC Wainwright lifted their price target on Eton Pharmaceuticals from $65.00 to $70.00 and gave the company a “buy” rating in a report on Friday. Four equities research analysts have rated the stock with a Buy rating and two have assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $67.50.

About Eton Pharmaceuticals

Eton Pharmaceuticals, Inc is a specialty pharmaceutical company focused on developing, manufacturing and commercializing generic and proprietary pharmaceutical products for patients with rare and underserved diseases. Headquartered in West Palm Beach, Florida, the company leverages its expertise in hormone therapies and complex molecules to address treatment areas where patient need is high and competition is limited. Since its founding in 2016, Eton has sought to build a diversified portfolio that combines established generic medicines with targeted branded offerings.

The company’s product lineup includes thyroid hormone replacements such as desiccated thyroid and liothyronine, as well as pyrimethamine tablets indicated for toxoplasmosis.